Aerpio Therapeutics Announces Positive Results of a Phase 2a Study of AKB-9778 in Diabetic Macular Edema: The TIME-2 Trial
CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced top-line results from its TIME-2 study of AKB-9778 in DME. The combination of AKB-9778 (dosed at 15 mg BID) and Lucentis® (ranibizumab injection) provided a clinically significant benefit in reduction of central subfield thickness (CST) compared to Lucentis® alone (p=0.008). In association with this improvement in CST, a positive trend also sh
